KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Operating Margin (2019 - 2025)

Historic Operating Margin for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to 70.11%.

  • Royalty Pharma's Operating Margin fell 600700.0% to 70.11% in Q3 2025 from the same period last year, while for Sep 2025 it was 65.22%, marking a year-over-year decrease of 29100.0%. This contributed to the annual value of 57.1% for FY2024, which is 62800.0% down from last year.
  • According to the latest figures from Q3 2025, Royalty Pharma's Operating Margin is 70.11%, which was down 600700.0% from 36.26% recorded in Q2 2025.
  • Royalty Pharma's 5-year Operating Margin high stood at 134.23% for Q2 2021, and its period low was 85.31% during Q4 2022.
  • For the 5-year period, Royalty Pharma's Operating Margin averaged around 51.91%, with its median value being 50.19% (2024).
  • As far as peak fluctuations go, Royalty Pharma's Operating Margin plummeted by -1119600bps in 2022, and later skyrocketed by 1881400bps in 2023.
  • Quarter analysis of 5 years shows Royalty Pharma's Operating Margin stood at 26.65% in 2021, then plummeted by -420bps to 85.31% in 2022, then skyrocketed by 221bps to 102.82% in 2023, then tumbled by -41bps to 60.9% in 2024, then grew by 15bps to 70.11% in 2025.
  • Its Operating Margin stands at 70.11% for Q3 2025, versus 36.26% for Q2 2025 and 94.01% for Q1 2025.